Community pharmacy valproate safety audit launched by CCA

Community pharmacy valproate safety audit launched by CCA

June 18, 2018

A new clinical audit has been created by the Company Chemists’ Association (CCA), host of the Community Pharmacy Patient Safety Group, to explore community pharmacy’s contribution in supporting girls and women of childbearing potential in taking valproate medicines.

The first phase of the audit starts in July 2018 and the second phase starts in November 2018. The audit is split into four sections and should be completed in stages. CCA member companies will be disseminating the audit resources directly to their pharmacy teams over the next few weeks so that they can participate, however, all community pharmacy teams can participate in the audit.

All data will be submitted via a weblink and will help to inform the monitoring activities of the Valproate Stakeholder Network, convened by the Medicines & Healthcare products Regulatory Agency.

Further information, including forms, instructions and resources, can be found on the CCA website.

Further information on clinical audit is available on PSNC’s Clinical audit page.

Commenting on the launch, Alastair Buxton, Director of NHS Services, at PSNC said:

“Patient safety is always a priority in community pharmacy and this audit provides a great opportunity to make a difference to patient safety by focussing on a high-risk medicine associated with birth defects and developmental disorders. Community pharmacy teams are in an ideal position to provide information and advice to women and girls who have been prescribed this medicine, ensuring they get the crucial support they need.

This audit is an excellent option for contractors to complete to meet the Community Pharmacy Contractual Framework requirement to undertake a practice-based clinical audit.”

 Kate Livesey, Policy & Programmes Manager at the CCA commented:

“Community pharmacy teams play a vital role in the care of patients taking these high-risk medicines. Given the importance of this year’s topic, we would like to see pharmacy teams from all across the country getting involved in our audit and reviewing their current practice. We’re really keen to build a body of evidence from across the whole sector that demonstrates what pharmacy teams are doing to improve care and minimise the risk of harm around valproate in pregnancy.”

 



Posted in: ,


More Latest News >